human growth hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Treosulfan, sold under the brand name Trecondi among others, is an alkylating medication given to people before they have a bone marrow transplant from a donor known as allogeneic hematopoietic stem cell transplantation. It is used as a 'conditioning' treatment to clear the bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells. It is used together with another medicine called fludarabine in adults and children from one month of age with blood cancers as well as in adults with other severe disorders requiring a bone marrow transplant. It belongs to the family of drugs called alkylating agents. In the body, treosulfan is converted into other compounds called epoxides which kill cells, especially cells that develop rapidly such as bone marrow cells, by attaching to their DNA while they are dividing. DNA cross-linking is considered a primary mechanism underlying the pharmacological action of treosulfan, and epoxides formed from treosulfan may cross-link DNA via at least two chemical pathways. Preclinical studies in animal models have shown that treosulfan is widely distributed to the liver, lungs, bone marrow, and skeletal muscle, with tissue-to-plasma ratios of 0.96, 0.82, 0.82, and 0.77, respectively. Lower biodistribution was observed in the brain and the aqueous humor of the eye (both 0.10). In juvenile rats with an immature blood–brain barrier, brain exposure was higher (0.15) than in young adult rats.
=== Tanning and early stuffing techniques === Preserving animal skins has been practiced throughout human history. For example, embalmed animals have been found with Egyptian mummies. In Tenochtitlan, the capital of the Aztec Empire, taxidermy was a common practice, not only for preserving animals, but also because it held a deep symbolic value within Aztec culture. Eagles had the most symbolic impact; a particular cut mark on an eagle's skull indicates its having received treatment to taxidermize it. An important find in the remains of Tenochtitlan is twelve golden eagles that were found near the monolith of the goddess Tlaltecuhtli. The eagles were found dressed with copper anklets and pectorals of wood on their chests. Through intricate ritual events with different objects, including the taxidermized eagle skulls, the people of Tenochtitlan believed that they could create a link between the earthly and the divine. Although embalming incorporates lifelike poses, it is not considered taxidermy. In the Middle Ages, crude examples of taxidermy were displayed by astrologers and apothecaries. The earliest methods of preservation of birds for natural history cabinets were published in 1748 by René-Antoine Ferchault de Réaumur in France. Techniques for mounting were described in 1752 by M. B. Stollas. There were several pioneers of taxidermy in France, Germany, Denmark, and England. For a while, clay was used to shape some of the soft parts, but this made specimens heavy. By the 18th century, a majority of towns had a tannery business.
Clifford insisted that no British troops should be committed for the suppression of the rebellion. In October, Clarke arrived at Wepener at the head of a force of 1,000 cavalry, 600 infantry, five artillery pieces, and 40 wagons. Clarke was aiming to relieve Mafeteng, whose garrison was forced to exchange messages written in Greek, since some Basuto chiefs spoke both English and French. Clarke's advance was slowed by deep mud, and the Basuto cavalry regularly harried the column with rifle fire before withdrawing. On 19 October, the Cape army reached Qalabane, an isolated kop halfway between Wepener and Mafeteng. Lerotholi had positioned 3,000 of his warriors behind a ridge that overlooked a nearby road. The advanced guard of the Cape Mounted Yeomanry came under rifle fire from the kop. Clarke ordered the artillery to fire upon the kop and dispatched 200 men from the 1st Cape Mounted Yeomanry to flank the kop from the left. CMY commander Captain Dalgety ordered his soldiers to dismount and assume an open order formation. Chief Seiso's led a charge of 300 axe-wielding Basuto cavalrymen on Dalgety's unit before the latter was able to reach the crest. The 2nd CMY reinforced Dalgety soon afterwards and captured a nearby village. The Cape army lost 32 killed and seven injured, while the Basuto lost 40 killed. The yeomanry was almost defenseless in hand-to-hand combat, as it was not yet issued bayonets or swords.
RNA-induced silencing complex (RISC) A ribonucleoprotein complex which works to silence endogenous and exogenous genes by participating in various RNA interference pathways at the transcriptional and translational levels. RISC can bind both single-stranded and double-stranded RNA fragments and then cleave them or use them as guides to target complementary mRNAs for degradation.
== Types == The structure of the nanotube is not changed if the strip is rotated by 60 degrees clockwise around A1 before applying the hypothetical reconstruction above. Such a rotation changes the corresponding pair (n,m) to the pair (−m,n+m). It follows that many possible positions of A2 relative to A1 — that is, many pairs (n,m) — correspond to the same arrangement of atoms on the nanotube. That is the case, for example, of the six pairs (1,2), (−2,3), (−3,1), (−1,−2), (2,−3), and (3,−1). In particular, the pairs (k,0) and (0,k) describe the same nanotube geometry. These redundancies can be avoided by considering only pairs (n,m) such that n > 0 and m ≥ 0; that is, where the direction of the vector w lies between those of u (inclusive) and v (exclusive). It can be verified that every nanotube has exactly one pair (n,m) that satisfies those conditions, which is called the tube's type. Conversely, for every type there is a hypothetical nanotube. In fact, two nanotubes have the same type if and only if one can be conceptually rotated and translated so as to match the other exactly. Instead of the type (n,m), the structure of a carbon nanotube can be specified by giving the length of the vector w (that is, the circumference of the nanotube), and the angle α between the directions of u and w may range from 0 (inclusive) to 60 degrees clockwise (exclusive). If the diagram is drawn with u horizontal, the latter is the tilt of the strip away from the vertical.
Sources: en.wikipedia.org
=== Allegations of manufacturing and product tampering === 26 April 2007 and 27 April 2007 recalls by Blue Buffalo, Diamond, Harmony Farms, and Natural Balance are claimed by all 4 brands to be due to unauthorized inclusion of rice protein by American Nutrition, Inc. (ANI), their manufacturer. This adds a new potential source of contamination and distrust, namely non-compliant contract manufacturers, beyond the original problematic Chinese ingredient suppliers. Diamond and Natural Balance refer to this as a "manufacturing deviation" by ANI. Blue Buffalo and Harmony Farms characterize this as "product tampering" by ANI. ANI's recall notice makes no comment on these allegations.
== Sources == "Leslie Stephen Ettre," Obituary, Hartford Courant, June 4, 2010. C. W. Gerhke, Chromatography: A Century of Discovery 1900–2000 : The Bridge to the Sciences/Technology Journal of Chromatography Library Vol. 64 (Elsevier, 2001), pp. 178 – 179. "Happy Birthday Professor Leslie S. Ettre," Chromatographia, (2007) 66 (5–6), 301.
In articulation morphology, the central and most basic concept is no longer morphological homology but transformation: transformation of ramification and articulation. This changes the most basic questions we ask. Instead of asking questions about morphological homology, we ask how ramification and articulation have changed during development and evolution. For this reason, articulation morphology may be considered a new paradigm of plant morphology. It changes fundamentally our way of thinking about morphology and morphological investigation.
== Components == Each generation of the Dexcom CGM system has consisted of two primary components: the sensor and the transmitter. The sensor is a thin wire that is inserted into the subcutaneous tissue, where it measures interstitial glucose levels. The transmitter is a small electronic device that attaches to the sensor and wirelessly transmits the glucose data to a compatible receiver, smartphone, or other monitoring device, allowing users to view their glucose readings in real time. The Dexcom G7 was the first Dexcom CGM to have an all-in-one sensor and transmitter. In addition to the sensor and transmitter, Dexcom CGM systems also include an applicator, which is the device used to insert the sensor into the tissue. Blood glucose readings are viewed on a device-specific receiver or modern systems via a smartphone application.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.